Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07527910 · ClinicalTrials.gov registry record · Phase 2
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
A Phase 2 study, sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 204
- Enrollment target
NCT07527910 is a Phase 2 study that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 204 participants.
The verdict
NCT07527910, a Phase 2 study, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 204 participants
- Enrollment target
Study Summary
This study will test a study drug called ALN-PNP with and without another drug that is used for controlling blood sugar, appetite, and weight (for example, tirzepatide), to see if it can help treat MASLD, also known as fatty liver disease. ALN-PNP reduces the amount of Patatin-like phospholipase domain-containing protein 3 (PNPLA3), a protein that liver cells make, which may help decrease liver fat if there is an abnormal PNPLA3 protein. The goal of this study is to understand the effect of ALN-PNP with or without tirzepatide on reducing liver fat. The study is looking at: * How well ALN-PNP with and without tirzepatide works * What side effects ALN-PNP might cause * How much ALN-PNP is in the blood at different times * How the body and the liver change after having ALN-PNP, which can help researchers understand why ALN-PNP works better in some people than others
Interventions
- DRUG Placebo
- DRUG Tirzepatide
- DRUG ALN-PNP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2026-05-22 |
| Est. Completion | 2030-03-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07527910
The ClinicalTrials.gov registry entry for NCT07527910 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07527910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07527910 about?
NCT07527910 is a clinical study titled "A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD". This study will test a study drug called ALN-PNP with and without another drug that is used for controlling blood sugar, appetite, and weight (for example, tirzepatide), to see if it can help treat MASLD, also known as fatty liver disease. ALN-PNP reduces the amount of Patatin-like phospholipase dom...
What is the current status of trial NCT07527910?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2026-05-22. Estimated completion is 2030-03-15.
What interventions are being tested in trial NCT07527910?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG), ALN-PNP (DRUG).
Who is sponsoring clinical trial NCT07527910?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.